Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(43%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph not_applicable
4
57%
Ph phase_2
1
14%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
N/ANon-phased studies
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Recruiting3
Completed2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (20.0%)
N/A4 (80.0%)

Trials by Status

completed229%
terminated114%
unknown114%
recruiting343%

Recent Activity

3 active trials
Showing 5 of 7
recruitingnot_applicable

Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

NCT03977571
recruitingnot_applicable

Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity

NCT07463508
completed

Endoscopic Characteristics of Duodenal and Ampullary Lesions

NCT01556399
recruiting

Inflammatory Profiling in Chronic Lung Disease

NCT04654767
terminatedphase_2

Vemurafenib Plus Cobimetinib in Metastatic Melanoma

NCT02414750
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03977571Not Applicable

Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

Recruiting
NCT07463508Not Applicable

Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor Chemosensitivity

Recruiting
NCT01556399

Endoscopic Characteristics of Duodenal and Ampullary Lesions

Completed
NCT04654767

Inflammatory Profiling in Chronic Lung Disease

Recruiting
NCT02414750Phase 2

Vemurafenib Plus Cobimetinib in Metastatic Melanoma

Terminated
NCT04349293Not Applicable

Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways

Unknown
NCT02358174Not Applicable

Hemorrhoids and Metalloproteinases, Observational Study

Completed

All 7 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
7